acute myeloid leukemia Articles
-
Near-atomic-level Details of Cancer Proteins with the Help of Molecular Cages Revealed
Sandwiching the wobble protein between two other layers allowed scientists to get the most detailed picture of a protein that is key to the spread of acute myeloid leukemia. Acute myeloid leukemia (AML) afflicts more than 20,000 Americans each year, killing more than 11,000 of them, according to the American Cancer Institute. And many people who receive intensive chemotherapy or stem cell ...
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
Persistent gene editing therapy using LNP-delivered mRNAs
Gene editing technology, represented by CRISPR/Cas9, has greatly accelerated the development of gene therapy, bringing hope to many genetic diseases that otherwise had no cure. In June 2021, Intellia Therapeutics' NTLA-2001, a CRISPR gene editing therapy for the treatment of transthyretin amyloidosis (ATTR) invented by Nobel Laureate Jennifer Doudna, was proven to be safe and effective in a ...
-
PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ...
-
What are the ADC drugs?
Antibody-drug conjugates (ADCs) continue to rise at home and abroad, but ADCs are not a new thing. Why has ADC been surging for so many years? What kind of magic power it contains, and what makes its growth path so tortuous? Let's take a brief look at the magical "magic bullet"-ADC. ADC (antibody-conjugated drug) is not a new concept. As early as the early 20th century, the Nobel Prize winner ...
By BOC Sciences
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
-
Antibody Drug Conjugates: "Biological Missiles" For Targeting Cancer Therapy
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
-
How to Design a Good ADC Drug
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you